Hamilton Thorne Shares Drop by 4.1%
March 2, 2023
Trending News 🌥️
HAMILTON ($TSXV:HTL): This decrease in the company’s stock is a surprise to investors, as the company had seen steady growth in recent months. The company had recently moved into a new market, and due to the competitive nature of the market, it is possible that the stock was affected. Additionally, there could have been internal issues that were previously unknown that contributed to the decrease. It is unclear if the stock will continue to drop or if it will rebound in the coming days.
Market Price
The stock opened at CA$1.6 and closed at the same price. The stock had been trading relatively steadily in the days prior to the drop. It is uncertain what caused the sudden dip in the stock’s share price.
The company, which provides advanced laser systems and imaging instruments for scientists, has yet to comment on the decrease in the stock’s value. Investors may be waiting to see how the stock fares in the days ahead. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Hamilton Thorne. More…
| Total Revenues | Net Income | Net Margin |
| 57.37 | 1.77 | 2.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Hamilton Thorne. More…
| Operations | Investing | Financing |
| 2.23 | -2.58 | -2.01 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Hamilton Thorne. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 70.27 | 17.5 | 0.37 |
Key Ratios Snapshot
Some of the financial key ratios for Hamilton Thorne are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.7% | -3.9% | 4.8% |
| FCF Margin | ROE | ROA |
| -0.6% | 3.2% | 2.5% |
Analysis
As GoodWhale, we analyzed the financials of HAMILTON THORNE and found that the company possesses a strong asset, growth, and profitability. However, it is weak in dividend. Based on the Star Chart, HAMILTON THORNE scored a 10/10 health score due to its capability to pay off debts and fund future operations. This makes HAMILTON THORNE classified as a ‘gorilla’, which means it has achieved stable and high revenue or earning growth due to a strong competitive advantage. Investors interested in HAMILTON THORNE should take note of the company’s potential high return on investment and relatively low risk of investment. With a strong ability to pay off debt and turn in a high profit, HAMILTON THORNE could be an attractive option for those investors seeking a long-term and reliable return on investment. Investors can also look forward to the company’s healthy dividend payouts in the future. More…
Peers
In the field of medical research equipment, there is intense competition between Hamilton Thorne Ltd and its main competitors, Hangzhou Alltest Biotech Co Ltd, Caina Technology Co Ltd, and Hainan Shuangcheng Pharmaceuticals Co Ltd. All of these companies are striving to develop the most innovative and effective products possible in order to gain market share. This competition is beneficial for consumers as it drives down prices and encourages companies to continuously improve their products.
– Hangzhou Alltest Biotech Co Ltd ($SHSE:688606)
Hangzhou Alltest Biotech Co Ltd is a biotechnology company that focuses on the research and development, production, and sales of in vitro diagnostic reagents and instruments. The company has a market capitalization of 6.37 billion as of 2022 and a return on equity of 27.91%. Alltest Biotech’s products are used in the fields of medical diagnosis, food safety, and environmental testing. The company’s products are sold to customers in China and overseas markets.
– Caina Technology Co Ltd ($SZSE:301122)
Caina Technology Co Ltd is a Chinese company that manufactures integrated circuits and other semiconductor products. It has a market capitalization of 5.22 billion as of 2022 and a return on equity of 7.44%. The company’s products are used in a variety of electronic devices and components, including mobile phones, computers, and automobiles. Caina Technology is headquartered in Shenzhen, Guangdong Province, China.
– Hainan Shuangcheng Pharmaceuticals Co Ltd ($SZSE:002693)
Hainan Shuangcheng Pharmaceuticals Co Ltd is a Chinese pharmaceutical company with a market cap of 4.59B as of 2022. The company’s ROE is -3.09%. The company manufactures and sells pharmaceutical products, medical devices, and health food products.
Summary
This decrease is extremely significant in the short-term, and could potentially have a lasting impact on Hamilton Thorne‘s performance. Analysts are keeping a close eye on Hamilton Thorne’s long-term growth prospects and stock price volatility. They will be evaluating the company’s fundamentals, including revenue growth potential, dividend history, and debt levels.
Additionally, analysts are monitoring industry trends, which could affect Hamilton Thorne’s competitiveness and success. In the end, the true measure of success for a company is based on its long-term growth potential and profitability. Hamilton Thorne still has some work to do in order to prove itself to investors and maintain a healthy stock price.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
